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ABSTRACT 
Affordability of medicines for patients with diabetes attending University of Nigeria 
Teaching Hospital (UNTH), Enugu 
 
Background: In developing countries, diabetes is the leading cause of blindness, renal failure and 
lower limb amputation with most deaths due to cardiovascular disease complications. The 
prognosis for diabetes is poor and life expectancy is short and akin to the era in which insulin 
was not available to manage diabetes (Beran et al., 2005). These poor outcomes have been 
attributed to chronic shortage and non-affordability of diabetic medicines. 
 
Aim: This study determined the affordability of medicines for diabetic patients attending the 
diabetic clinic of the University of Nigeria Teaching Hospital (UNTH), Enugu.  
 
Methods: The study was a cross-sectional, time-delimited, descriptive study of affordability of 
medicines for diabetic patients aged >18 years and who pay for medicines out-of-pocket. All 
eligible patients attending the diabetes clinic who are responsible for payment of their prescribed 
medicines were recruited between September 19 to October 31, 2007. A structured questionnaire 
was used to collect sociodemographic information about patients and the prescription was 
assessed in terms of conformity with the essential medicines list (EML), cost and ability to be 
completely filled by the patient. Data was analysed using EPI Info software.  
  
Results: Of the 189 respondents, 37% were able to completely fill their prescriptions with funds 
from income (40%), borrowed funds (15%) or gifts from friends/relatives (43%). The total 
number able to completely fill their prescriptions increased to 47% when substitutes from the 
EML were made. The mean number of days’ wages to completely fill the prescription was 6.5 
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days and this reduced to 4.8 days when the choice was made wholly from the EML. The prices 
patients paid to purchase the key medicines to manage diabetes and cardiovascular disease were 
2 to 26 times international reference prices.  
 
Conclusions: The results show that medicines prescribed for diabetes patients are unaffordable to 
the majority of patients who attend the UNTH diabetic clinic. While choice from the EML would 
have a positive impact on affordability, ability to afford out-of-pocket payment would also be 
greatly improved with reduction in prices patients pay for their medicines. There is need to 
restructure financing mechanisms for chronic disease management with the aim of reducing or 
abolishing out-of-pocket payments for medicines and health services in the country.  
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CHAPTER 1 – INTRODUCTION  
WHO (2006a) estimates that more than 180 million people world wide have diabetes and 
this figure is likely to double by 2030. In developing countries where more than 80% of 
diabetes deaths occur, the prevalence is likely to increase by 150% in the next 25 years. 
Thus, diabetes is a global threat to public health that is worsening particularly in the 
developing world. 
 
With globalization and epidemiological transition, most sub-Saharan African countries 
face the double burden of communicable and non-communicable diseases. The prognosis 
for diabetes is bleak in sub-Saharan Africa as two out of three diabetes patients will die as 
a result of cardiovascular complications (Kengne et al., 2005) and life expectancy for a 
child with newly diagnosed type 1 diabetes can be as short as seven months in rural 
Mozambique (Beran et al., 2005). This is mainly due to weak health systems which are 
primarily focused and experienced in acute care and have inadequate capacity and 
resources to effectively manage chronic diseases. In addition, the response of 
governments to this growing public health threat is grossly inadequate.  
 
Several studies have shown poor availability and affordability of essential medicines in 
developing countries (Mendis et al., 2007; FMOH, 2005). For example, despite the 
availability of insulin for almost a century, successive surveys carried out by the 
International Diabetes Federation (IDF) over the past 12 years have shown a chronic 
shortage and non-affordability of life-saving insulin in sub-Saharan African countries 
(Deeb et al., 1994; IDF, 2003; Beran et al., 2005). 
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WHO (2006b) suggests that Nigeria has the greatest number of people living with 
diabetes in Africa, with an estimated burden of about 1.7 million which will increase to 
4.8 million by 2030. The economic burden of diabetes is enormous in terms of the direct 
cost of intensive monitoring and control of blood glucose and managing cardiovascular, 
renal and neurological sequelae.   
 
Presently, Nigeria does not have standard treatment guidelines for managing people 
living with diabetes, although it developed its first essential medicines list in 1998.  
Prescribers are required to select medicines from the list but implementation has not been 
successful and they often choose medicines outside the list without due consideration to 
affordability, availability, safety and efficacy. The national standard treatment guidelines 
for the diseases of public health importance are currently being developed.  
 
In Nigeria, a substantial portion of health care costs is borne by the patient – 74.5% of the 
health care expenditure in 2003 (WHO, 2006b). The report also estimates that 90.2% of 
Nigerians live below the poverty level of 2 United States Dollars (USD) per day. Thus, 
affording health care will be a challenge to people living with diabetes in Nigeria. This 
difficulty is evidenced by the reports showing high prevalence of complications due to 
diabetes (Okesina et al., 1999; Unachukwu et al., 2007). 
 
In this study, I will explore affordability of medicines prescribed to people living with 
diabetes attending the diabetic clinic of a teaching hospital in Nigeria.  
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CHAPTER 2 – LITERATURE REVIEW: 
2.1.   Burden of diabetes 
 
There is a consensus that sub-Saharan African countries are facing a double burden of 
communicable and non-communicable diseases, with the incidence of diabetes rising 
steadily (Beaglehole and Yach, 2003). In a press release, the International Diabetes 
Federation (IDF) considers diabetes “the epidemic of the 21st Century” and estimates that 
80% of diabetic patients are in developing countries (IDF, 2006). Kengne and Mbanya 
(2006) reported that over the past two or three decades, the prevalence has increased by 2 
to 10 fold in most sub-Saharan African countries.  
 
The true prevalence of diabetes in sub-Saharan African countries is unknown although 
most studies provide varying estimates ranging from 0% to 10.4% (Sobngwi et al., 2001; 
IDF, 2003), making Africa the region with the lowest prevalence. This apparent low 
prevalence may represent an underestimation due to several factors related to the method 
of assessment, the insidious nature of the disease, weak health systems with inappropriate 
detection policies and practices, as well as poor access to health facilities (Kengne and 
Mbanya, 2006). For example, reported estimates are derived from death certificates and 
this underestimates the prevalence of diabetes because individuals with diabetes often die 
of cardiovascular and renal diseases (Roglic et al., 2005).Wild et al. (2004) noted that 
while most diabetes patients are >64 years in developed countries, the age range in sub-
Saharan Africa is between 45 – 64 years, thus studies that focus on the aged would 
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certainly miss most of the cases. More realistic estimates could be obtained through well 
designed population studies. In addition, systematic recording and analysis of mortality 
and morbidity data would help in revealing the true burden of diabetes.  
 
2.2:  Complications of diabetes 
WHO (2004) asserts that that complications and death due to diabetes can be prevented 
or delayed through effective management. The authors suggest that by combining healthy 
lifestyles and effective medications, people living with diabetes can lead full and healthy 
lives. Numerous authors have also demonstrated that intensive blood glucose control in 
diabetics not only reduces complications but increases the time they are free from 
complications (Gray et al., 2000; Group UPDS, 1998; Group DCaCTR, 1993). Therefore, 
access to health care and medicines required for appropriate glycaemic control is 
important to mitigate complications and premature mortality.  
 
The reality is that complications are rife in Africa and the IDF (2003) asserts that diabetes 
is now the leading cause of blindness, renal failure and lower limb amputation with 70 to 
80% of deaths due to cardiovascular disease complications.  
 
Estimates of the burden of complications are quite unreliable due to wide variability in 
study designs and paucity of information in many countries especially in sub-Saharan 
Africa (IDF, 2003; Abbas and Archibald, 2005). Thus, population based studies with 
standardized protocols are required to produce reliable estimates of prevalence of 
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complications that are comparable across countries and from one period to another (IDF, 
2003). 
2.3. Diabetes and poverty 
WHO (2005) concludes that poor people are more likely to develop chronic diseases, 
develop complications, and die after developing chronic diseases. The authors assert that 
the reason is that the poor are more likely to have material deprivation, psychosocial 
stress, high levels of risky behaviour, unhealthy living conditions and poor access to good 
quality health care.  For example, Bartley et al. (2000) suggest that risk factors of 
diabetes such as consumption of energy dense and high fat foods, physical inactivity, 
overweight or obesity are more likely to be present in the poor. In cases of ill health, the 
poor are also less likely to access good quality health care and diagnostic services due to 
financial constraints, lack of proximity to health care facilities, and poor responsiveness 
of the health care system (WHO, 2005)     
  
2.4.  Cost of diabetes 
Diabetes exerts a heavy toll on individuals, their families and nations in terms of human 
suffering and economic costs.  WHO (2004) estimates that the burden of premature death 
from diabetes is similar to that of HIV/AIDS yet the problem is largely unrecognised by 
governments. The authors also reveal that loss of life from premature death from diabetes 
is greatest in developing countries despite the greater prevalence in developed economies.  
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This is due to the fact that people with diabetes in developing countries generally die at a 
younger age that in the developed world. Thus, loss of life, disability and the consequent 
effect on quality of life and productivity, are hindrances to economic growth. It is 
reported that some countries spend as much as 2.5% to 15% of annual health care budgets 
only on diabetes and up to five times the amount spent on diabetes on lost productivity 
(WHO, 2003).  
 
Most studies on the cost of diabetes relate only to direct costs of treatment in health 
facilities. There is little or no publication on indirect and intangible costs of diabetes 
although it is increasingly affecting the productive segment of the society and 
consequently impacting on economic growth and poverty levels of individuals in 
countries. In sub-Saharan Africa, most of the health care costs are borne by individuals 
and their families and this may explain why there is little interest in economic cost of the 
disease studies. Most available studies are carried out in established economies whose 
governments play a greater role in the health care provision of the populace.  
 
Thus, in situations where the responsibility for bearing the cost of treatment falls fully on 
the individual and his family, when care is unaffordable, individuals are left to the 
consequences of non-treatment. This is usually translated into high rate of morbidity and 
mortality from poor glycaemic control and resulting complications.  In their review, 
Kengne and Mbanya (2006) showed that indeed mortality was reported to be high with 
life expectancy of type 1 diabetics at diagnosis not exceeding 5 years in most African 
countries. 
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2.5. Out-of-pocket costs and diabetes 
Several studies have linked out-of-pocket expenditure with barriers to care especially for 
patients with chronic diseases (Piette et al., 2004a; Karter et al., 2003; Hsu et al., 2006). 
There is ample evidence to show that with Medicare beneficiaries in the United States 
cost sharing caused a reduction in drug consumption (Rector and Venus, 2004; Tseng et 
al., 2004) and poorer adherence to prescribed medication (Rector and Venus, 2004; 
Tseng et al., 2004; Cox et al., (2001). In a review, Hsu et al., (2006) demonstrated that 
when patients had no insurance coverage for medicines, they had lower rate of use of 
essential medicines, higher rates of visits to the emergency room and death. 
 
 While such studies abound in developed countries there are few studies which relate the 
consequences of out-of-pocket or lack of insurance to health care in developing countries. 
Some studies have shown that poor patients who cannot afford their medications shop 
around with traditional medicine practitioners, drug sellers or even avoid medical treatment 
and this worsens their conditions (WHO, 2004). Aikins (2005) in a qualitative study of 
diabetic patients in Ghana was able to reveal that diabetic patients considered biomedical 
management as ideal. However, due to non affordability of diabetic medicines and care, 
they were driven to cure seeking with ethnomedical systems of care which resulted in 
diabetic complications. Also in Mexico, self-medication and use of complementary 
medicines in diabetic patients were associated with being uninsured (Pegan and Puig, 
2005).  
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2.6. Access to diabetes medicines  
Many studies in developed countries have identified non adherence to a complex regimen 
of medical care and lifestyle modification required to manage the disease, as the prime 
factors in the development of complications and premature death of people living with 
diabetes (Cramer, 2004; Group UPDS, 1998; Group DCaCTR, 1993). In developing 
countries, the situation is very different. For type 1 diabetics and a large percentage of 
type 2 diabetics, the availability of medicines and testing facilities can dictate the 
morbidity and mortality patterns due to the disease. Thus, access to diabetic medications 
and technology is required in order to save lives of diabetics and minimise complications. 
In contrast to developed countries where most diabetic care is covered by insurance, most 
of the people living with diabetes in developing countries pay for management of their 
condition out-of-pocket. This constitutes a barrier to appropriate control of diabetes.   
 
Poor access to medicines is an intractable problem in developing countries and has been a 
key focus of the WHO since the initiation of its essential medicines program in 1977. The 
need to secure affordability and geographical access has been recognized, with 
affordability being the most important determinant of accessibility to life saving 
medicines (Everard, 2002). Several studies have testified to poor availability and high 
cost of diabetes medicines in African countries (Mendis et al. 2007) including Nigeria 
(FMOH, 2005). As mentioned earlier, Beran et al., (2005) suggest that the life 
expectancy of diabetic children in some sub-Saharan African countries is comparable to 
pre-insulin era due to poor access to the life saving medicine.  
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2.7. Essential Medicines List (EML) and affordability 
Although effective medicines to treat many diseases were known by 1970, half of the 
world population did not have access to these medicines due to non availability, non 
affordability, poor quality and inappropriate use (WHO, 1998). In 1977 the essential drug 
concept was born with the drawing up of the first Essential Medicines List. This list 
contained carefully chosen medicines made on the basis of efficacy, safety and 
comparative cost-effectiveness. These medicines were those that satisfy the priority 
health care needs of the majority of the population and were required to be available in 
health facilities at all times in adequate amounts (WHO, 1998).  
 
Although the concept was well accepted by many countries and international 
organisations like the World Bank, it has not made the anticipated impact on health 
outcomes (WHO, 1997). This is due to a number of factors including direct opposition to 
the concept by the pharmaceutical industry whose sale of expensive medicines was 
threatened; and doctors who viewed their freedom to prescribe restricted and others who 
felt that essential medicines were “poor man’s medicine” (Weerasuriya and Brudon 
(1998). Furthermore, Weerasuriya and Brudon (1998) suggested that political 
commitment, poor implementation strategies and numerous stakeholders with differing 
interests have prevented countries from benefiting from the full potential of essential drug 
concept.  
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2.8. Nigerian health system  
About 40% of the population in Nigeria utilise the public health facilities. The Nigerian 
public health system is pluralistic and uncoordinated and managed by the three levels of 
government namely the federal, the states and the local governments. These three levels 
all have responsibility for health and thus each has a specific domain of influence. The 
federal government has responsibility for policy formulation and management of tertiary 
hospitals, the state governments for secondary health facilities, while the local 
government authorities, the primary health facilities. Thus, there is little or no 
stewardship of the levels by the central government.  
 
The tertiary and secondary facilities, who manage people living with diabetes, run as 
autonomous bodies. Funds are usually allocated to the facilities to cater for all needs 
without any earmarking for procurement of medicines. There is usually full recovery of 
funds for all services including prescribing, laboratory testing, hospitalisation and 
medicines. This means that patients pay for all diabetes services out-of-pocket including 
medicines.  
 
Nigeria drew up its first essential medicines list in 1988 and it was backed by Essential 
Drugs Law which mandated prescribing, procurement and use of medicines to be limited 
to the EML. Implementation of the concept has not been effective as physicians still 
prescribe any medicines they deem appropriate for the patient. In addition, there is 
unhindered access of industry representatives to prescribers and several studies have 
shown their influence in the choice of newer, more expensive medicines (Caudill et al., 
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1996; Lexchin, 1997; Caamaño et al., 2002, Wilkes, Doblin and Shapiro, 1992; Styrer 
and Bero, 1996; Powers et al., 1998). The facility pharmacies tend to stock medicines 
which are usually prescribed, to reduce incidence of patients not having their 
prescriptions filled in the health facility. This results in stocking and procuring medicines 
which are not on the essential medicines list and which are expensive. This in turn 
impinges on availability as scarce resources are used to procure a few expensive 
medicines. 
 
Medicine procurement in the country is also adhoc and facility based. This means that 
medicines are unaffordable due to lack of transparency and non exploitation of economy 
of scale to reduce the overall cost of medicines.  
 
A survey of medicine prices in Nigeria showed that facilities both in public and private 
sectors charged between 2 to 64 times international prices (FMOH, 2005) and most  of 
the targeted medicines had very low availability in the facilities. Glibenclamide, an 
essential medicines in the treatment of diabetes, was found to cost more than 17 times 
international price in the public sector (FMOH, 2005). Availability was also found to be 
low for metformin (28.6%) and glibenclamide (45.2%). While the survey did not seek out 
availability and affordability of insulin, IDF, (2006), reported that in recent assessments 
in 25 countries in Africa, insulin was regularly available in large hospitals in half of the 
countries and only in 5 countries in rural facilities. 
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WHO (2006c) describes affordability in terms of the number of days the lowest paid 
government worker would work to afford medicines. The reality is that most Nigerians 
do not work for the government. FMOH (2005) tried to identify factors which might 
contribute to the high cost of medicines at the national level such as taxes and tariffs, 
mark-ups at the level of importers, manufacturers, wholesalers and retailers. The role of 
selection in the affordability of medicines at the prescriber level was not considered.  
 
Enugu which is the study setting, is a typical state capital in Nigeria and the inhabitants 
consist mainly of subsistence farmers, petty traders and a smaller number of government 
employees. Due to the fragmented and poor functioning of the health system in Nigeria, most 
patients seek help directly at secondary and tertiary facilities which are nearest to them. This 
is because health professionals are concentrated in urban areas and such health facilities 
provide the only possibility patients have to receive appropriate care for chronic illnesses. 
Most patients who attend public health facilities in Nigeria are poor. 
 
This study will thus examine affordability of medicines prescribed to patients attending 
the diabetic clinic at the University of Nigeria Teaching Hospital, Enugu.  
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CHAPTER 3 – RESEARCH DESIGN AND METHODOLOGY 
3.1 Aim 
The aim of the study is to conduct a situation analysis of affordability of medicines 
prescribed to diabetic patients attending the University of Nigeria Teaching Hospital in 
Enugu  
 
3.2. Objectives 
• To determine the socioeconomic status of people living with diabetes attending 
University of Nigeria Teaching Hospital, Enugu 
• To determine the percentage of patients who can completely fill their prescriptions from 
the hospital pharmacy 
• To calculate the percentage of prescribed medicines selected from the essential medicines 
list (EML) for patients attending the diabetic clinic in the hospital 
• To compare affordability of medicines as prescribed by the physician with those totally 
conforming to the EML 
• To compare patient prices of key medicines used to treat diabetes and its co-morbidities 
with international reference prices. 
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3.3.  Definition of terms  
Definitions of 
affordability  
1. Ability to completely fill the prescription 
2. A prescription that costs equal or less than one days’ 
income 
3. Medicine prices costing less or equal to 1.5 times the 
international reference price 
 
International Reference 
Price  
 
The MSH issues an annual International Price Indicator Guide 
of prices offered by not-for-profit suppliers to developing 
countries for multisource generically equivalent products 
 
Daily wage 
 
Total personal monthly income ÷ 30 days 
 
Number of days’ wages 
to purchase medicine 
 
Total cost of prescription ÷ daily wage 
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3.4. Study Design:  
The study was a cross sectional descriptive time delimited study of affordability of medicines 
prescribed for diabetic patients paying out-of-pocket, as it relates to selection of medicines 
from the national essential medicine list by prescribers. 
  
3.5. Study Population:  
The study population is adult diabetic patients aged more than 18 years, who are managed at 
the University Teaching Hospital Enugu diabetic clinic run once every week and who pay for 
their medications out-of-pocket.  
3.6. Sample Size:  
The sample size was calculated using Epi Info Stat Calc. According to the 2006 census, 
Enugu state has a population of 3.5million persons.  The calculation of the study population 
was based on the 75% of the population in Nigeria that pay out-of-pocket for the health needs 
(WHO, 2006b), that 40% of the population utilise public health facilities, that 60% of the 
population are adults and the prevalence of diabetes is 2.8% among adults. Also considering 
that there are two teaching hospitals in the Enugu state the study population was estimated to 
be 6,300 persons. Based on preliminary assumption that about 10% of the target population 
cannot completely fill their prescriptions and with a degree of error of 5% and a power of 
95%, our sample size was calculated to be 113 patients. 
 
 
 
 
 
 16
3.7. Sampling Procedure:  
Patients with type I or type II diabetes attending the diabetic clinic at UNTH, Enugu, who 
have been prescribed any medicine used for treating diabetes were recruited. Since most 
diabetics have other diseases such as hypertension, the full range of medicines prescribed for 
the patients was assessed.  Those who pay the full cost for their medications were included in 
the study, while those on any form of insurance or third party payment (e.g. employer) were 
excluded.  
 
3.8. Data Collection:  
A structured questionnaire (appendix 1) was used to collect data between 19 September and 
31 October, 2007.  The questionnaire was pre-tested on 10 diabetic patients attending the 
health facility prior to commencement of the study and minor changes were made.  
 
The data collection took into consideration the procedure for service delivery to diabetic 
patients. At the diabetic clinic run every Wednesday, the patient first sees the physician who 
writes a prescription for medicines. The patient then goes to the pharmacy department where 
the prescription is evaluated and priced and handed over to him to pay at the finance 
department. If the patient cannot pay the full cost of the prescription, the pharmacy 
department costs part of it in relation to how much the patient can afford. After the 
adjustment is made the patient pays at the finance department, collects a receipt and then 
goes back to the pharmacy to collect medicines.  
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I used two pharmacists to collect data. The first data collector filled in the background 
information on patients at the waiting room of the diabetes clinic. The second data 
collector completed the details of the prescription as well as the amount the patient paid 
for the medicines. All patients attending the diabetes clinic, and fulfilling the study 
criteria, were included in the study and data collection continued until the required 
number of patients had been recruited. 
 
Subsequently, the completed questionnaires were then examined to determine those which 
had medicines prescribed outside the approved National Essential Medicines List. 
Appropriate alternatives were suggested by two clinical pharmacologists at the University of 
Lagos, Nigeria.  Since there is no officially approved protocol for the management of 
diabetes, the draft Nigerian Standard Treatment Guidelines which is currently being pre-
tested by some secondary and tertiary institutions was used as a reference to guide to the 
pharmacologists. Where the choices were different, a third specialist adjudicated between the 
selections. The cost of the medicines prescribed and alternatives suggested by the experts 
were determined from the current hospital price list. Where the medicines were not available 
in the facility, the cost in the closest private pharmacy was used to determine the price the 
patient would pay for the prescribed medicine.  
 
3.9. Data analysis:  
The completed instruments were further cross checked and appropriate sections were 
completed and entered into Microsoft Access by the researcher and later exported into Epi 
Info software for analysis. Double entry of all data was done to ensure accuracy of entry. The 
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entered data was subsequently cleaned by the researcher who generated the full set of 
descriptive data for all the variables and examined them for errors.  
 
Descriptive statistics were generated using the Epi Info software. The sample 
characteristics, affordability and medicine selection were described using means or 
median and frequency and the extent of dispersion of data was demonstrated by the 
confidence interval.  
 
Affordability was described in terms of the ability of a patient to completely fill the 
prescription as adherence to a diabetic regimen is essential to control the disease and 
mitigate against development of complications. I also measured the proportion of patients 
able to pay for their medicines with one days’ income. The prices patients were required 
to pay for their medicines were also compared to international prices (MSH, 2006). 
Medicine prices were deemed affordable when they did not cost more than 1.5 times 
international reference prices (Mendis et al., 2007). 
 
Medicine selection was described according to percentage of medicines prescribed from 
the EML. The difference between the cost of prescriptions written by the physician and 
the alternative regimen from the EML suggested by the clinical pharmacologists, was 
assessed using a two-tailed t-test. The severity of diabetes in terms of patients with 
diabetes only and those with other co-morbidities such as hypertension was stratified and 
analysed.  
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To assess patient prices, unit cost of medicines of the same strength was compared with 
international reference prices (MSH, 2006). Patient prices which cost more than 1.5 times 
international prices were deemed unaffordable. The researcher was solely responsible for 
the analysis of data. 
 
 
3.10. Validity/Reliability:  
The sample calculation was based on 95% confidence level and 5% margin of error in order 
to obtain a large enough sample to limit the likelihood of chance influencing the results. All 
attendees at the clinic within the data collection period were approached. Data was collected 
throughout the day to ensure inclusion of people from different backgrounds who may prefer 
some specific time in the day to visit the clinic.  
 
Measurement bias was minimized by first of all designing the data collection tool to be 
simple, short and appropriately formatted to reduce error of data collection and entry into the 
database. The data collectors were also adequately trained and the tool was piloted so that 
requisite skills were acquired before undertaking the survey. Pharmacists were employed as 
data collectors to ensure correct interpretation of prescriptions. 
 
3.11. Ethical Considerations:   
The proposal was approved by the Ethics Committee of the University of the Western 
Cape and permission was granted by the Ethics committee of the University of Nigeria 
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Teaching Hospital. The aims and purposes of the research were explained to the patients 
verbally either in English or Ibo (Appendix 2) and written informed consent (Appendix 3) 
was obtained. The participants were assured of confidentiality and anonymity and that 
their decision to participate was not intended to affect their treatment at any time. 
Participants were also informed that they were free to withdraw from the study at any 
stage without any adverse consequences to them.  As the study did not involve any 
invasive procedures I did not anticipate any adverse psychological or emotional reaction 
from respondents. Participants were made to understand that the study results and 
recommendations will be communicated to UNTH hospital management board as well as 
the Federal Ministry of Health. 
  
3.12.  Limitations  
The ideal design would have been a multistage sampling in which the first stage would be 
random sampling from the list of all secondary and tertiary health facilities in the sample 
frame. Thereafter, the patients attending the sampled facilities would in turn be randomly 
sampled in proportion to usual attendance rate to the clinics. This was not logistically feasible 
due to the cost that will be required to implement such a self funded study. The consequences 
of this might be over representing some groups of patients who may have a preference for the 
teaching hospital over other facilities. I have tried to minimise the sampling bias by 
increasing the sample size and collecting data throughout the day.  
 
The choice of an alternative medicine from the EML may have been done without the full 
appreciation all the underlying causes which the prescribing physician would have taken into 
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consideration. This would thus mean comparing the cost of medicines which are not strictly 
equivalent. However, I tried to minimize this by ensuring alternatives from the EML have 
very similar characteristics and can be used for patients with similar underlying pathologies.  
 
Obtaining valid information on expenditure was very difficult and often incomplete as the 
participants did not always know how much they spend habitually. This was especially true 
for farmers who may have most of their income in kind (farm produce).  However, I was able 
to measure this critical information on the patients.  
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CHAPTER 4: RESULTS: PRESENTATION AND DISCUSSION   
4.1. Results  
In order to ascertain affordability of medicines prescribed for diabetic patients attending 
the diabetic clinic of the University Teaching Hospital Enugu, a total of 189 patients were 
interviewed between 19 September  and 31October, 2007.  
 
4.1.1.  Socioeconomic background   
Table 1 shows that there were more females (62%) than males and the mean age of 
diabetic patients was found to be 56 years. The age distribution of diabetics attending the 
health facility shows a predominance (61%) of respondents between the ages of 45 to 65.   
The majority of the respondents are married and about two thirds of them have little or no 
educational attainment. About two thirds of the respondents are employed and one third 
are retired. Table 2 shows that although most of them are employed, they are mostly 
engaged in petty trading, subsistence farming and blue collar government jobs as civil 
servants.  
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Table 1: Demographic variables (N =189) 
Variable  Number Percentage Measure of dispersion  
Sex  
Male 
Female 
 
72 
117 
 
 38% 
62% 
95% Confidence Interval (%) 
31.1 – 45.4  
54.6 – 68.9 
Age    
Median age (years) 
 
56 
 
 
Range 
22 – 85 
Age group 
 
20 - 44 
45 - 64  
65+ 
 
 
29  
110  
41  
 
 
16%  
61% 
22%  
95% Confidence Interval (%) 
 
11.1 – 22.3  
53.6 – 68.3 
16.9 – 29.6 
Marital status  
Single 
Married  
Widowed 
 
6 
160 
23 
 
3% 
85% 
12% 
95% Confidence Interval (%) 
1.2 – 6.8 
78.7 – 89.5 
7.9 – 17.7 
Educational attainment  
None 
Primary 
Secondary 
Tertiary  
 
41 
73 
38 
36 
 
22% 
39% 
20% 
19% 
95% Confidence Interval (%) 
16.1 – 28.4 
31.8 – 46.2 
14.7 – 26.7 
13.8 – 25.5 
Employment status 
Employed 
Unemployed  
Retired  
 
111 
22 
56 
 
59% 
12% 
30% 
95% Confidence Interval (%) 
51.4 – 65.8 
7.4 – 17.1  
23.2 – 36.7 
 
Table 2: Occupation of employed respondents (N=111) 
Type of occupation No Percent  
Professionals 14 13 
Civil servants 18 16 
Commercial activities (petty traders) 61 55 
Subsistence farmers 12 11 
Household employees 6 5 
 
Table 3 shows that most of the respondents earn very low income as more than one third 
(38%) earn less than 2 USD per day (table 4). It is important to note that regular gifts 
from friends and relatives are also included in the income. Their disposable incomes are 
not enough to meet their routine needs as their median expenditure (18,000 naira) is more 
than their median income (12,000 naira). About one out of every 10 respondents do not 
earn any income and are thus themselves dependent on others as they are either 
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housewives or students. The median number of dependents is 3 and a majority of them 
came to the clinic with funds given to them as gifts by relatives and friends or borrowed. 
It is therefore clear that most of the people living with diabetes attending this health 
facility do not have the financial capability to pay for their medicines or other needs 
related to their conditions.   
 
Table 3: Socioeconomic variables (N = 189) 
Variable  Value Measure of dispersion 
 
Median personal monthly income 
(N=181) 
 
N12,000 
Interquartile range (25% - 75%) 
5,000 – 30,000 
 
Median day’s wage (N=181) 
 
N 400 
Interquartile range (25% - 75%) 
167 – 10,000 
 
Median monthly expenditure (N=161) 
 
N 18,000 
Interquartile range (25% - 75%) 
500 – 200,000 
 
Median number of dependants (N=189)  
 
3 
Interquartile range (25% - 75%) 
1 – 6 persons   
Source of funds used to purchase 
medicines 
Income  
Borrowed  
Gift  
Sold property 
Percent  
 
83 (42%) 
34 (16%) 
95 (44%) 
3   (1%) 
95% Confidence Interval (%) 
 
32.1 – 51.0 
9.7 – 20.2 
34.9 – 49.4 
0.3 – 4.6 
 
Table 4: Distribution of income in USD per day (N=181) 
USD/day Number  Percent Cumulative percent 95% Confidence Interval (%) 
0 15  8.3 8.3% 4.7 – 13.3  
1 38  21.0 29.3% 15.3 – 27.7 
2 17  9.4 38.7% 5.6 – 14.6  
3-5 47  26.0 64.6% 19.7 – 33.0  
6-10  31  17.1 81.8% 11.9 – 23.4  
>10   33  18.2 100.0% 12.9 – 24.6  
 
 
4.1.2.  Medical and prescription information   
 
A majority of the respondents (67%) had other conditions in addition to diabetes. Of 
those who had other conditions, hypertension (56%) and eye problems (9%) were the 
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most prevalent. Leg ulcer was not common with these diabetics. They also complained 
mainly of arthritis and peptic ulcer disease.  
On the average, the respondents had 5.5 medicines prescribed for them. Most of the 
medicines prescribed were on the essential medicines list with an average of 5 medicines 
conforming to it. Of those not conforming to the EML, 20% of them had at least one item 
prescribed as fixed dose combination. While the median cost of the prescriptions was 
2942 naira, the median cost paid by respondents was just about the half (1585) of this 
median cost. Only 37% of patients were able to completely fill their prescriptions.   
 
Table 5: Medical history   (N= 189) 
Variable Number Percent 95% confidence interval 
Co-morbidity 
Yes  
No  
 
126 
63 
 
67 
33 
 
59.5 -.73.3 
26.7 – 40.5  
Other conditions apart from diabetes 
Hypertension  
Eye problem 
Leg ulcer 
Other diseases 
Arthritis  
Peptic ulcer disease  
Miscellaneous  
 
106 
17 
2 
 
10 
7 
8 
 
56 
9 
2 
 
36 
32 
32 
 
48.7 – 63.3 
5.3 – 14.0 
0.1 – 3.8 
 
21.1 – 61.3 
12.1 – 49.4 
 
 
 
Table 6: Prescription details (N=189) 
Variable  Value Measure of dispersion 
 
Average number of items per prescription 
 
5.6 
Std deviation  
1.7 
 
Average number of medicines prescribed 
from the EML  
 
 
5 
 
 
1.8 
Percentage of prescriptions with at least one 
fixed dose combination  
 
 
38 (20%) 
95% confidence interval 
 
14.7 – 26.7 
 
Median cost per prescription in Naira 
 
N2862 
Interquartile range (25% - 75%) 
1720 – 4816  
 
Median amount paid by patients in Naira 
 
N1585 
 
0 – 6525  
Prescription completely filled 
Yes  
No 
 
69   (37%) 
120 (64%) 
95% confidence interval 
29.6 – 43.8 
56.3 – 71.3 
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4.1.3.  Effect of choice of medicines from the EML on affordability  
With the help of clinical pharmacologists, medicines which were selected outside the EML were 
substituted with equivalent ones from the EML. The affordability measures were then used to 
assess if there was any difference in ability of the patients to afford their medicines.   The results 
showed some reduction in median cost of prescriptions by 778 naira (figure 1) and a reduction in 
the median number of days’ wage required to afford the medicine by 1.7 (figure 2) and 10% 
increase in the number of patients who could completely fill their prescriptions (figure 3).  
 
Figure 1: Median cost per prescription
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Figure 3: Percentage of patients that 
filled all prescriptions 
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4.1.4.  Effect of co-morbidity on affordability of prescription 
 
When the cost of medicines for those suffering from only diabetes was compared with those with co-
morbidities no significant difference in the median cost per prescription was found (table 7). There 
was also no significant difference between the number of patients able to fill their prescriptions with 
or without co-morbidities. However, the mean number of days that patients will work to be able to 
afford their medications was significantly higher in relation to the patients with other conditions. This 
may suggest that the patients with co-morbidities had lower income than those with only diabetes. 
 
Table 7: Comparison of cost of medicines with severity of disease  
Variable Severity 
Diabetes  
only 
Diabetes with other 
co-morbidities 
P value  
Median cost per prescription (naira) 2558 2991 0.3235 
% of patients that fill all prescriptions 37 37 0.5886 
Median number of days’ wages to pay 
for the prescription                
4.3388 7.8493 0.0063 
 
 
 
 
 
4.1.5. Effect of UNTH prices on affordability of prescriptions 
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Patient prices for key medicines used to treat diabetes and co-morbidities were compared 
with international reference prices. The results in table 8 showed that the patient prices 
for all medicines ranged from 2 to 26 times international price. This indicates that prices 
charged by the facility for medicines contributed to non affordability of these vital 
medicines used to manage diabetes and co-morbidities. 
 
Table 8: Comparison of unit cost of key medicines for diabetes and cardiovascular 
disease in UNTH with International Reference Price (IRP) 
  IRP Median 
cost/unit ($) 
IRP Median 
price/unit 1(N) 
UNTH patient 
prices (N) 
Ratio  
Insulin 70/30 0.9384 117.3 231 2
Artovastatin 10mg 0.8075 100.9 170 2
Metformin 500mg 0.017 2.1 4.6 2
Hydralazine 25mg 0.0227 2.9 6.5 2
Methyldopa 250mg 0.0272 3.4 8.5 3
Fluvastatin 20mg 0.4305   53.8 170 3
Spironolactone 100mg 0.036 4.5 11.5 3
Propranolol 40mg 0.0055 0.7 3 5
Amlodipine 10mg 0.2388 29.9 155 5
Furosemide 40mg 0.0048 0.6 3.5 6
Tramadol 50mg 0.0688 8.6 50 6
Lisinopril 10mg 0.0698 8.7 62.5 7
Ofloxacin 400mg 0.0979 12.3 85 7
Hydrochlorothiazide 50mg 0.0038 0.5 3.5 8
Warfarin 5mg 0.0414 5.2 48 9
Nifedipine R 20mg 0.0189 2.3 22.5 10
Glibenclamide 5mg 0.0036 0.5 5 11
Enalapril 5mg 0.0164 2.1 25.5 12
Gliclazide 0.0254 3.2 82.5 26
Mean ratio     6
 
                                                 
1 1 US$ is N125 
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4.2. Discussion 
In the management of chronic diseases, access to essential medicines is very important in 
order to prevent suffering and premature mortality and complications. This study sought 
to ascertain the ability of diabetic patients attending UNTH, Enugu to procure their 
medicines after their regular visit to the physician.  
 
4.2.1. Socioeconomic status  
The results show that the people living with diabetes attending the clinic in UNTH 
represent the lower income, poorly educated and more elderly members of the 
population.  Other reports from Nigeria and other countries show diabetics having similar 
sociodemographic characteristics (Karter et al., 2003; WHO, 2005; Okoro, Adejumo and 
Oyejola, 2002; Akanji, 2002). The results also debunk the commonly misunderstood 
notion that chronic diseases mainly affect rich people (WHO, 2005). The authors assert 
that the poor are more likely to suffer from diabetes and progress more rapidly into 
complications and death than the non-poor.  Changing the mindset of prescribers, 
dispensers and the community may have a positive impact on the policies on chronic care 
especially as it affects access to medicines. 
 
The age distribution in this study is different from those of developed countries but 
congruent with the age range in which there is higher prevalence of diabetes in 
developing countries. Wild et al., (2004) demonstrated that diabetes afflicts the 45 – 65 
age range in developing countries in contrast to > 64-year range in developed countries.  
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In this study about two thirds of the respondents were women. Wild et al., (2004) also 
reported that although the prevalence of diabetes is similar in men and women, there are 
more women who are diabetics than men. The sex distribution found in this study may 
not be a true reflection of the proportion of male and female diabetics in the population. 
There may be other factors responsible for more women visiting this particular facility. 
Researching such reasons is beyond the scope of this study. Only a well designed 
population based study may be able to provide the true sex distribution of diabetics in the 
population.  
 
4.2.2.  Medicine financing 
The results show that patients in this study generally spend more than they earn and are 
saddled with the responsibility of other dependants. It is therefore clear that they cannot 
assume the responsibility of financing the management of their conditions effectively. 
Inability to procure needed medicines to appropriately manage chronic conditions in the poor 
may be the reason why WHO (2005) asserted that poor patients who suffer from chronic 
diseases are more likely to develop complications. Other authors (Rector and Venus, 2004; 
Tseng et al., 2004; Cox et al., 2001; Hsu et al., 2006) have also demonstrated that when the 
poor are not supported through insurance and social security, they have reduction in drug 
consumption, poorer adherence to prescribed medication, higher emergency room visits and 
death. Other authors (Kengne and Mbanya, 2006; Okoro, et al., 2002) have associated the 
poor prognosis of diabetes in sub-Saharan African countries to poor access to vital 
medicines.  To remedy this, the government needs to review its policies regarding financing 
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of medicines and supplies required for the management of chronic diseases to exclude out-of-
pocket sources especially for the poor who are suffering from chronic conditions.  
 
The results also show that there is a high level of solidarity among friends and relatives in the 
care of the less endowed members of the community as most of the diabetics were funded by 
them. This phenomenon of health care funding by friends and relatives was also reported by 
some authors (Okoro et al., 2002; Ogunniyi and Baiyewu, 2002. However, funding from 
charity or from the extended family system is unsustainable for the management of long-term 
health problems. Nevertheless, it could be exploited to provide social security for those less 
privileged members who cannot afford to fully support their health care needs. Indeed health 
insurance schemes in cultures with strong social support as the extended family system 
should not be patterned after western models.  They should exploit the existing framework 
whereby relatives and friends naturally feel responsible for sustaining the less endowed 
members.  
 
The health insurance scheme in the country which is currently in its infancy urgently needs to 
be restructured. This is because only organisations employing more than 10 persons currently 
contribute towards the scheme and others are required to join on a voluntary basis. Again the 
scheme is managed by Health Management Organisations (HMOs) who are traditionally 
known to “cream” the rich in the society. Mechanisms to ensure the participation of the poor 
in insurance schemes are strongly advocated especially for those who have chronic diseases.  
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4.2.3.  Affordability 
The study clearly demonstrates that medicines were not affordable to the majority of patients 
visiting the diabetic clinic. Several studies have used various affordability measures to 
determine financial access to medicines. In this study, I have measured it in several ways. 
Firstly I have considered ability of the patient to completely fill the prescription during the 
visit. While this measure is a very important indicator as adherence is key to appropriate 
management of diabetes, it does not completely uncover the extent of the problem. This is 
because most of patients admitted to visiting the clinic with funds which were from 
relatives/friends or borrowed. In this study, only about one third of the patients were able to 
go home with the full complement of prescribed medicines despite most of them being 
financially supported. This is a clear indication of non affordability.  
 
Secondly, affordability was measured in terms of the number of days a person will work to 
be able to afford his medication. WHO (2006c) suggested that a prescription that will require 
more than one day’s wage is considered unaffordable. This measure seems reasonable to 
determine the ability to pay for medicines as data available suggest that the poorest families 
in Nigeria spend as much as 90% of their income on food alone (Federal Office of Statistics, 
1999). Therefore, procurement of needed medicines should not compete with other basic 
needs such as feeding. The median number of days of 6.5 days measured in this study 
indicates that the prescriptions were generally out of reach of most of the patients. The 
extreme case of the patient who will need to work for 15 years to afford the month’s 
prescription is worthy of note. 
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Affordability was also considered in terms of medicines selected with reference to the 
essential medicines list. This measure makes the assumption that only cost-effective 
medicines are included in the list. This may not always be the case as a list is determined by 
practitioners in the country, it may mirror irrationality in the system and may not alwaysbe 
developed following transparent processes. For example the Nigerian essential medicines list 
has both captopril and lisinopril on the list, both medicines are from the same class which is 
important in managing co-morbidities associated with diabetes. While captopril costs 12.5 
naira in the facility, lisinopril costs 43 naira which represents almost 4 times the cost of the 
former. One would have thought that given the socioeconomic state of the patient population, 
captopril which is also selected in the WHO Model List, would have been the more rational 
choice. In this study, adherence to the EML was high but the medicines were not affordable. 
This indicates that the use of EML adherence is not very sensitive in measuring affordability.  
 
Finally, affordability was measured in terms of cost of individual medicines purchased in the 
facility. Patient prices for key medicines were measured against international reference 
prices. Medicines which were purchased more than 1.5 times international price were 
deemed unaffordable (WHO, 2006c). While this measure is useful in determining the role of 
patient prices in contributing to affordability, it may give a false sense of security in that too 
many items on the prescription may render the prescription unaffordable. The median ratio of 
6 for key medicines used for diabetics found in this study is clearly excessive and has shown 
that patient prices has contributed to the inability of most patients to fill their prescriptions.  
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The study suggests that the most sensitive measure of affordability is the ratio of cost of the 
prescription to the patient’s income. Affordability measures such as prescribing from the 
EML and assessing procurement prices in relation to international prices serve to identify 
factors affecting affordability which will help the facility design interventions to improve 
affordability.  
 
4.2.4.  Selection of medicines 
4.2.4.1.  Prescriber adherence to medicines list  
Realising that the selection of medicines have a role to play in determining the quality of care 
and affordability of medicines, the World Health Organization has promoted the concept of 
essential medicines for 30 years. Thus WHO publishes a list of carefully selected, cost-
effective medicines to guide countries in the choice of their national list. This study was also 
aimed at assessing the adherence of prescribers to the national list as a proxy to measuring 
affordability of prescriptions.  
 
The results show that adherence of prescribers to the list was quite high. Further analysis 
showed that indeed, prescribing from the EML was a first step to ensuring affordability of 
medicines. However, the few medicines selected outside the list had a profound effect on 
affordability. The results show that despite the high price charged by the facility for 
medicines, a significantly higher number of patients would have gone home with most of 
their prescriptions filled had the prescribers adhered completely to the EML.  
 
Despite the initial reticence reported by Weerasuriya and Brudon (1998) in which the 
essential drugs list was not making the requisite impact, due to oppositions by the 
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pharmaceutical industry, prescribers themselves and the public, the WHO has consistently 
developed and reviewed Model Lists to guide the development of national lists for the past 
30 years. This has helped in the global acceptance of the concept of essential medicines as a 
powerful tool to promote health equity. By the end of 2003, 156 Member States had official 
essential medicines lists and have reaped benefits of increased availability and affordability 
of essential medicines in health facilities. There is evidence that carefully selected lists and 
standard treatment guidelines are effective in ensuring appropriate prescribing (Grimshaw 
and Russell, 1993; Woolf et al., 1999; Kafuko and Bagenda, 1994).   
 
4.2.4.2. Fixed dose combinations 
One out of every five medicines which was selected outside the EML was a fixed dose 
combination product. In the case of glibenclamide and metformin which are cornerstones in 
the management of diabetes, the fixed dose combination is nine times more expensive than 
individual components. While fixed dose combinations are promoted to improve adherence, 
it may not be useful for economically challenged patients living with diabetes whose primary 
concern is first and foremost ability to acquire their medicines.  Grant et al., (2003) reported 
that adverse drug reactions and out-of-pocket prescription costs were better predictors of 
adherence than polypharmacy. It is possible that the clinicians use fixed-dose combination to 
mitigate poor adherence to therapy without realising that it exacerbates the very condition 
which they try to remedy. This indicates lack of communication between patients and 
clinicians. Indeed, some authors have reported lack of communication regarding cost of 
medicines with health care providers as a reason for poor adherence (Piette et al., 2004b). 
The authors provided several reasons why patients did not call attention of the physician to 
their plight. Some reasons include failure of the clinician to initiate discussions on ability to 
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afford the prescription, insufficient time for discussions in the consulting room and 
perception that the clinician was unable to provide any form of help. Mason et al., (2001) 
also showed that it is difficult to enforce cost considerations among prescribers.  
 
WHO (2001) encourages the use of single compounds except when fixed-dose combinations 
have proven advantage in therapeutic efficacy, safety or compliance over single compounds 
administered separately. The use of fixed combination of glibenclamide and metformin does 
not really meet these criteria as there is no enhanced benefit of combining both in a 
formulation. An obvious disadvantage is the difficulty in adjusting dosage of any of the 
components to meet the need of individual patients should there be a need to titrate the 
dosage to individual needs.  
 
4.2.4.3. Dispensing practices 
The fact that patients were not able to procure all their medicines raises an important question 
related to the management of chronic diseases. The practice in the facility is to sell part of the 
prescription according to ability of the patient to pay for them. What criteria are used to 
determine which medicines to sell to patients? Do the patients return to the facility to 
purchase more medicines? These questions need to be further investigated in order to 
understand the implications of non-affordability to the management of chronic diseases 
especially diabetes. Certainly, inability to completely fill prescriptions during the normal 
hospital visit will impact negatively on adherence. Factors such as inability to obtain more 
funds, transportation costs and other competing activities may militate against patients 
returning to the facility to procure more medicines.  
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4.2.5.  Predictor of affordability – EML or patient prices 
The results appear to indicate that choice of non-EML medicines definitely has a negative 
effect on affordability of medicines in this study. However, patient prices would seem to 
exert more influence on ability to fill prescriptions by patients. The most prescribed 
medicines were glibenclamide, metformin and lisinopril. While the cost of metformin was 
considered acceptable when compared with expected patient cost in relation to international 
prices, those for glibenclamide and lisinopril were clearly too expensive (11 and 7 times 
international reference prices respectively). Better patient prices would have made greater 
difference in the proportion of patients able to afford all their medicines.  
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CHAPTER 5: CONCLUSIONS AND RECOMMENDATIONS 
In this study, I have assessed the affordability of prescriptions given to diabetic patients who 
attend University of Nigeria Teaching Hospital, Enugu. I found that, like in other settings 
people living with diabetes have lower income, are poorly educated and are more elderly 
members of the population. They are clearly not able to provide adequate finances for 
procurement of medicines required to manage their chronic illnesses in order to prevent 
premature mortality and development of complications. The government should review the 
financing of health care particularly for medicines used to manage chronic illnesses 
especially with the changing epidemiological transition that is already underway. This is to 
ensure that patients with chronic conditions and those from the low economic stratum of the 
society have access to life saving medicines. They may well explore the already available 
solidarity existing between relatives and friends to evolve a more sustainable and equitable 
means of financing health care for all Nigerians.  
 
The study revealed that most of them were not able to completely fill their prescriptions for 
the management of their conditions. I identified the selection outside the EML contributory 
to the non affordability of essential medicines. As clinical guidelines have been found to be 
effective in rational prescribing, the national treatment guidelines which are currently being 
developed for major conditions of public health importance need to be institutionalised in 
health facilities in the country in order to support clinicians in prescribing. The UNTH should 
develop mechanisms to monitor treatment of people living with diabetes in order ensure 
patient access to medicines, prescriber adherence to the EML, and improved communication 
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between all departments. This could be achieved by institutionalising a Drugs and 
Therapeutics Committee at the facility.  
 
The study also revealed that prices charged by the institution for medicines contributed in no 
small measure to the non affordability of medicines of this group of patients. The pharmacy 
department of the UNTH should explore means of procuring medicines at lower prices 
against the benchmark of international reference prices. This will greatly enhance ability of 
patients to completely fill their prescriptions. 
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APPENDICES 
Appendix 1: Data collection tool 
 
Background information  
1. What is your first name?  
 
 
2. What is your date of birth?          Age 
 
 
  
3. Sex:    
 
 
4. What is your marital status? 
1 Single  3 Widowed  
2 Married  4 Divorced/separated  
 
5. Which highest level of education did you pass? 
1 None  3 Secondary education    
2 Primary education  4 Tertiary education  
 
6. What is your employment status?    
1 Unemployed   
2 Employed    
3 Retired   
 
7. What is your occupation?   
 
 
8. State your dependants 
Spouse  
1 Yes   
2 No    
 
Children  
1 Yes    If yes, how many?  
2 No   
 
Others  
1 Yes    If yes, how many?  
2 No    
 
 Total number of dependants  
 
1 Male   
2 Female  
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9. What is the usual monthly income of your household? (complete all that apply) 
Your job/pension  Relatives’ 
job/pension 
 Rent  
 
Stocks  Trading   Others  
 
Regular monetary gifts   Total   
 
 
10. What is the usual monthly expenditure of your household? (complete all that apply) 
Rent 
 
 Food   Transportation   
School fees 
 
 Others  Total  
 
11. Where did you get funds for purchase of medicines prescribed today? 
1. Income  
2. Borrowed  
3. Gift from relatives/friends  
4. Sold property  
5. Others specify  
 
12. Do you have any other diseases apart from diabetes? 
1 Yes   
2 No    
 
 
 
 
13. How much did you pay for your medicines today?   
 
 
23Prescription details  
SN  Name of medicine  # of units 
(tabs,  
cap, ml) 
EML  
(No = 0  
Yes = 1)
Unit cost Total cost  Substitute  
From EML
Unit cost Total 
cost 
1.         
2.         
3.         
4.         
5.         
6.         
7.         
8.         
9.         
10.         
Total          
                                                 
2The shaded parts are to be filled after the interview 
3 The darker shade is not to be filled at all 
If yes, specify  
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Appendix 2: Patient Information Sheet 
  
 
 
 
               UNIVERSITY OF THE WESTERN CAPE 
 
School of Public Health 
 
Private Bag X17 ● BELLVILLE ● 7535 ● South Africa 
Tel: 021- 959 2809, Fax: 021- 959 2872 
PARTICIPANT INFORMATION SHEET 
1. This is a survey to measure the affordability of medicines to treat diabetes in patients who 
come to this clinic. The medicines which your doctor has prescribed will be assessed and the 
amount which you paid to obtain your medications will be requested from you.  
 
2. The purpose of the research is to ensure that the cost of medicines to patients does not 
constitute a barrier to proper management of diabetes. This is because, strict adherence to 
medicines used to treat diabetes is required to live longer and healthier lives.   
 
3. Since the researcher works with the government to improve availability and affordability of 
medicines, information obtained will be presented to policy makers and recommendations on 
how to improve the situation will be made to them.  
 
The researchers will also like to publish the results in a journal in which the outcomes will be 
shared with other people. 
 
4. I will only need you to provide information about your background and the medicine the 
doctor has prescribed for you. Therefore, I do not anticipate any adverse result from this 
interview  
 
5. I will kindly request you to grant me permission to interview you; 
 
6. You may withdraw from the interview at any time if you no longer wish to participate. I will 
not be offended and it will not lead to any negative consequence to you in any way.  
 
7. Your identity will be kept confidential and I will not indicate your full name in any part of the 
data collection tool nor the publication. The results will be an aggregate of data collected 
from all respondents. 
 
8. The name of the researcher is Ogori Taylor (+2348034068096, tayloro@ng.afro.who.int) and  
her supervisor is Hazel Bradley (+2721 959 2630 hbradley@uwc.ac.za) 
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Appendix 3: Consent Form 
 
RECORD OF INFORMED CONSENT TO CONDUCT AN INTERVIEW     
Date:                     
Interviewer:  
UWC Student no: 2520547 
Tel: +2348034068096 Fax: + 234 94618725 
E-mail: tayloro@ng.afro.who.int 
Institution: School of Public Health, University of the Western Cape 
Place at which the interview was conducted:  __________________________________________ 
 
Thank you for agreeing to allow me to interview you. What follows is an explanation of the purpose and process of this 
interview. You are asked to give your consent to me verbally before I conduct the interview. 
 
1. Information about the interviewer 
I am Ogori Taylor a student at the SOPH, University of the Western Cape. As part of my Masters in Public Health, I am 
required to conduct a research on diabetic medicines at UNTH, Enugu. I will be focusing on affordability of medicines to 
patients living with diabetes. I am accountable to Hazel Bradley who is contactable at +2721 959 2630 or c/o SOPH Fax: 
021 959 2872 or by e-mail at hbradley@uwc.ac.za 
Here is some information to explain the purpose and usage of my interview. 
 
2. Purpose and contents of interview  
The purpose of the research to find out if medicines prescribed for people living with diabetes who attend this hospital 
are affordable to them. This is to ensure that cost of medicines does not constitute a barrier to proper management of 
diabetes. You will be required to respond to a few questions and show us your prescription. 
 
3. The interview process 
I will only need you to provide information about your background, the medicines the doctor has prescribed for you 
and the cost you paid for it. Therefore, I do not anticipate any adverse result from this interview  
 
4. Anonymity of contributors  
At all times, your identity will be kept confidential and I will not indicate your full name in any part of the data 
collection tool nor any publication derived from the study. The results will be an aggregate of data collected from all 
respondents.  
 
5. Things that may affect your willingness to participate  
Although I do not foresee any adverse effects emanating from the interview, you may however withdraw from the 
interview at any time if you no longer wish to participate. I will not be offended and it will not lead to any negative 
consequence to you in any way.  
 
6. Agreement 
6.1 Interviewee's agreement 
The respondent will be asked to give her/his consent verbally.  
 
6.2 Interviewer's agreement 
I shall keep the contents of the above research interview confidential in the sense that data will be aggregated and no 
mention will be made of any of the participants in particular. The contents will be used for the purposes referred to above, 
but may be used for published or unpublished research at a later stage without further consent. Any change from this 
agreement will be renegotiated with you. 
 
Signed:                                 
Date: 
Place: 
 
 
 
 
